Log in

Relevant bibliographies by topics / Beta adrenergic receptor blockaders / Books

To see the other types of publications on this topic, follow the link: Beta adrenergic receptor blockaders.

Books on the topic 'Beta adrenergic receptor blockaders'

Author: Grafiati

Published: 4 June 2021

Last updated: 21 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 25 books for your research on the topic 'Beta adrenergic receptor blockaders.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Cruickshank, J. M. Beta-blockers in clinical practice. Edinburgh: Churchill Livingstone, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Prichard, Brian N. C. 1932-, ed. Beta-blockers in clinical practice. Edinburgh: Churchill Livingstone, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Drugs looking for diseases: Innovative drug research and the development of the beta blockers and the calcium antagonists. Dordrecht: Kluwer Academic Publishers, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Advances in adrenergic receptor biology. Amsterdam: Elsevier, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Owens, Helen. The effect of beta-adrenergic receptor antagonists on the temporal accommodative response. Birmingham: Aston University. Department of Vision Sciences, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

1944-, Costello J. F., and Mann Ronald D. 1928-, eds. Beta agonists in the treatment of asthma: The proceedings. Carnforth, Lancs, UK: Parthenon Pub. Group, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Richard, Beasley, and Pearce Neil, eds. The Role of beta receptor agonist therapy in asthma mortality. Boca Raton: CRC Press, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

1946-, Frishman William H., ed. Beta₃-adrenergic agonism: A new concept in human pharmacotherapy. Armonk, N.Y: Futura, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Cruickshank, J. M. Beta-Blockers in Clinical Practice. 2nd ed. W.B. Saunders Company, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

1948-, Deedwania Prakash C., ed. Beta-blockers and cardiac arrhythmias. New York: M. Dekker, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

1955-, Burch Ronald M., ed. Bradykinin antagonists: Basic and clinical research. New York: Dekker, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

H, Birkenhäger W., Folkow Björn, and Struyker-Boudier H. A. J, eds. Adrenergic blood pressure regulation: Proceedings of a symposium, Corfu, 22-25 May 1984. Amsterdam: Excerpta Medica, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

R, Bühler Fritz, ed. The Cardioselectivity of bisoprolol. Montreal: PharmaLibri, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

The effect of training on beta adrenergic receptor number in rat heart. 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

15

Beasley, Richard, and Neil E. Pearce. Role of Beta Receptor Agonist Therapy in Asthma Mortality. Taylor & Francis Group, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

16

Beasley, Richard, and Neil E. Pearce. Role of Beta Receptor Agonist Therapy in Asthma Mortality. Taylor & Francis Group, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

17

Beasley, Richard, and Neil E. Pearce. Role of Beta Receptor Agonist Therapy in Asthma Mortality. Taylor & Francis Group, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

18

Pearce, Neil, and Richard Beasley. Role of Beta Receptor Agonist Therapy in Asthma Mortality. Taylor & Francis Group, 2019.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

19

Beasley, Richard, and Neil E. Pearce. Role of Beta Receptor Agonist Therapy in Asthma Mortality. Taylor & Francis Group, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

20

Frishman, William H., and Daniel E. Goldberg. Beta3 Adrenergic Agonism: A New Concept in Human Pharmacotherapy. Futura Publishing Company, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

21

Formoterol: A Long Acting B2-Agonist for the Management of Asthma : An International Symposium Held During the Joint Meeting of Sep and Sepcr, London. Hogrefe & Huber Pub, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

22

1936-, Saunders Kenneth B., European Society for Clinical Respiratory Physiology., and European Society of Pneumology, eds. Formoterol: A long-acting B2-agonist for the management of asthma : an international symposium held during the joint meeting of SEP and SEPCR, London, 1990. Seattle: Hogrefe & Huber, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

23

Formoterol. Hogrefe & Huber Pub, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

24

De Backer, Daniel, and Patrick Biston. Vasopressors in critical illness. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0034.

Full text

Abstract:

Vasopressors are used in various shock states to correct hypotension, aiming at restoring or improving organ and tissue perfusion. Vasopressor therapy may be associated with excessive vasoconstriction, but also metabolic and other side-effects. Hence, the ideal target for arterial pressure remains undetermined. Adrenergic agents remain the most commonly used vasopressor agents. Adrenergic agents increase arterial pressure through stimulation of alpha-adrenergic receptors. The effects of the different adrenergic agents differ mostly due to variable associated beta-adrenergic effects. Epinephrine and norepinephrine are strong and equipotent vasopressor agents. Their impact on outcome is as yet unanswered, but there is no sign that epinephrine might be associated with better outcomes. Accordingly, norepinephrine is the adrenergic agent of choice, especially in patients with cardiogenic shock. Vasopressin is a non-adrenergic vasopressor acting via V1 receptor stimulation, with weak vasopressor effects in normal conditions, but markedly increased vascular tone in shock states, especially in septic shock. Splanchnic vasoconstriction may occur. Arginine vasopressin at low doses appears to be a promising alternative to adrenergic agents, but its exact place is not yet well defined.

APA, Harvard, Vancouver, ISO, and other styles

25

1946-, Barnes Peter J., Matthys Heinrich, and European Society of Pneumology. Congress, eds. Formoterol--a new-generation [beta] 2-agonist: An international symposium held during the 8th Congress of the European Society of Pneumology, Freiburg, Federal Republic of Germany, September 1989. Toronto: Hogrefe & Huber, 1991.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!